Dasatinib induced pleural effusions - Reply
Keywords:
.References
1. Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med. 2010 Jul;16(4):351-6.
2. Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci. 2009;338(5):414.
3. Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol. 2013;31(2):103. Epub 2012 Jul 19.
4. Kathula SK. Dasatinib in chronic myelogenous leukemia. N Engl J Med. 2006 Sep;355(10):1062; author reply 1063-4.
5. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377
6. Yassin MA, El-Ayoubi HR, Kamzoul RT. Efficacy and safety of Dasatinib 50 mg once daily dose in patients with chronic phase CML who failed IMATINIB. Blood. 2011;118:21.
7. Abdulla MA, Amer A, Nawaz Z, Abdullah AS, Al-Sabbagh A, Kohla S, Nashwan A, Yassin MA. An uncommon case of chronic myeloid leukemia with variant cytogenetic. Acta Biomed. 2018;89(3-s):28-32.
2. Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci. 2009;338(5):414.
3. Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol. 2013;31(2):103. Epub 2012 Jul 19.
4. Kathula SK. Dasatinib in chronic myelogenous leukemia. N Engl J Med. 2006 Sep;355(10):1062; author reply 1063-4.
5. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377
6. Yassin MA, El-Ayoubi HR, Kamzoul RT. Efficacy and safety of Dasatinib 50 mg once daily dose in patients with chronic phase CML who failed IMATINIB. Blood. 2011;118:21.
7. Abdulla MA, Amer A, Nawaz Z, Abdullah AS, Al-Sabbagh A, Kohla S, Nashwan A, Yassin MA. An uncommon case of chronic myeloid leukemia with variant cytogenetic. Acta Biomed. 2018;89(3-s):28-32.
Downloads
Published
19-03-2020
Issue
Section
E-LETTERS: COMMENTS AND RESPONSES
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
1.
AJ Abdulla M, Yassin MA. Dasatinib induced pleural effusions - Reply. Acta Biomed [Internet]. 2020 Mar. 19 [cited 2024 Jul. 18];91(1):144-5. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/9263
